CWP
CTIC

Concord Wealth Partners’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

Concord Wealth Partners’s Portfolio CTIC Stock Details CTIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-3
Closed – – 1434
2021
Q4 		$0 Buy
+3
New +$7 ﹤0.01% 1375
2021
Q1 		– Sell
-9
Closed – – 1094
2020
Q4 		$0 Buy
+9
New +$30 ﹤0.01% 700

Other funds holding CTIC

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
LPC
Lion Point Capital New York $20.9M AUM 195.52% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
BL
Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Concord Wealth Partners's CTIC Position: Q1 2022 in Review

Concord Wealth Partners sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q1 2022, closing a stake of 3 shares.

Concord Wealth Partners first reported a position in CTIC in Q4 2020 and held it in 2 quarters. The position peaked at $0 in Q4 2021. 92 funds tracked by Wall St. Rank hold CTIC as of Q1 2022.

  • Concord Wealth Partners reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q1 2022 after selling out during the quarter.
  • Concord Wealth Partners sold 3 CTI BioPharma Corp. (DE) Common Stock shares in Q1 2022.
  • Concord Wealth Partners first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q4 2020 and held it in 2 quarters.
  • Concord Wealth Partners's CTI BioPharma Corp. (DE) Common Stock position peaked at $0 in Q4 2021.
  • 92 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q1 2022.

Based on Concord Wealth Partners's 13F filing for Q1 2022, filed 20 Apr 2022.